The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes

Bone

Volumn 35, Issue 3, 2004, Pages 766-770

  Braatvedt, G D ^a   Bagg, W ^a   Gamble, G ^a   Davidson, J ^b   Reid, I R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Atorvastatin; Bone turnover; Type 2 diabetes

Indexed keywords

ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; ATORVASTATIN; BETA C TELOPEPTIDE OF TYPE 1 COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; INSULIN; MARKER; METFORMIN; OSTEOCALCIN; PLACEBO; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PLASMA; RANDOMIZED CONTROLLED TRIAL; SERUM;

BIOLOGICAL MARKERS; BONE REMODELING; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; PYRROLES;

EID: 4344674934     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.05.001     Document Type: Article

References (27)

1. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949
2. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 283:2000;3205-3210
3. Wang P.S., Solomon D.H., Mogun H., Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 283:2000;3211-3216
4. Chan K.A., Andrade S.E., Boles M., Buist D.S., Chase G.A., Donahue J.G., et al. Inhibitors of hydroxymethylglutaryl-coenzyme a reductase and risk of fracture among older women. Lancet. 355:2000;2185-2188
5. Edwards C.J., Hart D.J., Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet. 355:2000;2218-2219
6. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., Nicholson G.C. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis study. Arch. Intern. Med. 162:2002;537-540
7. Chung Y.S., Lee M.D., Lee S.K., Kim H.M., Fitzpatrick L.A. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J. Clin. Endocrinol. Metab. 85:2000;1137-1142
8. Wada Y., Nakamura Y., Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch. Intern. Med. 160:2000;2865-2866
9. van Staa T.P., Wegman S., de Vries F., Leufkens B., Cooper C. Use of statins and risk of fractures. JAMA. 285:2001;1850-1855
10. Pedersen T.R., Kjekshus J. Statin drugs and the risk of fracture. 4S study group. JAMA. 284:2000;1921-1922
11. Reid I.R., Hague W., Emberson J., Baker J., Tonkin A., Hunt D., et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet. 357:2001;509-512
12. LaCroix A.Z., Cauley J.A., Pettinger M., Hsia J., Bauer D.C., McGowan J., et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the women's health initiative observational study. Ann. Intern. Med. 139:2003;97-104
13. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial. Lancet. 360:2002;7-22
14. Bauer D.C., Mundy G.R., Jamal S.A., Black D.M., Cauley J.A., Ensrud K.E., et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch. Intern. Med. 164:2004;146-152
15. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J. Clin. Endocrinol. Metab. 86:2001;4556-4559
16. Rejnmark L., Buus N.H., Vestergaard P., Andreasen F., Heickendorff L., Larsen M.L., et al. Effects of simvastatin treatment in postmenopausal osteogenic women: a randomized controlled trial. J. Bone Miner. Res. 18(Suppl. 2):2003;A1119. (S32)
17. Whitfield J.F. Statins: new drugs for treating osteoporosis? Expert Opin. Investig. Drugs. 10:2001;409-415
18. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19:2000;26-37
19. Bjarnason N.H., Riis B.J., Christiansen C. The effect of fluvastatin on parameters of bone remodelling. Osteoporosis. Int. 12:2001;380-384
20. Stein E.A., Farnier M., Waldstreicher J., Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr. Metab. Cardiovasc. Dis. 11:2001;84-87
21. Mostaza J.M., De la Piedra C., Curiel M.D., Pena R., Lahoz C. Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clin. Chim. Acta. 308:2001;133-137
22. Kajinami K., Takekoshi N., Matsui S., Kanemitsu S., Okubo S., Kanayama S., et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 29:2003;1113-1116
23. Kuzuya M., Suzuki Y., Asai T., Koike T., Kanda S., Nakamura A., et al. Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly. J. Am. Geriatr. Soc. 51:2003;1677-1678
24. Bouillon R., Bex M., Van Herck E., Laureys J., Dooms L., Lesaffre E., et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J. Clin. Endocrinol. Metab. 80:1995;1194-1202
25. Reid I.R., Ames R.W., Orr-Walker B.J., Clearwater J.M., Horne A.M., Evans M.C., et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am. J. Med. 109:2000;362-370
26. Reid I.R., Ames R.W., Evans M.C., Gamble G.D., Sharpe S.J. Effect of calcium supplementation on bone loss in postmenopausal women. NEJM. 328:1993;460-464
27. Bauer P.C., Garnero P., Bilezikian J.P., Greenspan S.L., McGowan J.A., Palermo L., et al. Effect of PTH, alendronate, or PTH plus alendronate on biochemical markers of bone turnover: one year results of the PaTH study. J. Bone Miner. Res. 18(Suppl. 2):2003;A1115. (S31)